Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
Authors:
- Kalijn F BolKBKalijn F Bol
- Erik H J G AarntzenEAErik H J G Aarntzen
- Florentien E M In 'T HoutFHFlorentien E M In 'T Hout
- Gerty SchreibeltGSGerty Schreibelt
- Jeroen H A CreemersJCJeroen H A Creemers
- W Joost LesterhuisWLW Joost Lesterhuis
- Winald R GerritsenWGWinald R Gerritsen
- Dirk J GrunhagenDGDirk J Grunhagen
- Cornelis VerhoefCVCornelis Verhoef
- Cornelis J A PuntCPCornelis J A Punt
- Johannes J BonenkampJBJohannes J Bonenkamp
- Johannes H W de WiltJWJohannes H W de Wilt
- 5 June 2015
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (1) , e1057673
Abstract
Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (p = 0.018; hazard ratio 0.59; 95%CI 0.42–0.84). Five-year survival rate increased from 38% to 53% (p < 0.01). In summary, in melanoma patients with regional metastatic disease, who are at high risk for recurrence and metastatic disease after RLND, adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune responses in the majority of patients and these were related to clinical outcome. OS was significantly higher compared to matched controls. A randomized clinical trial is needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.Keywords
This publication has 42 references indexed in Scilit:
- Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based VaccinationCancer Research, 2013
- Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic MelanomaCancer Research, 2012
- Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?Annals of Surgical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus MacrometastasesJournal of Clinical Oncology, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor MicroenvironmentClinical Cancer Research, 2007
- Morbidity and prognosis after therapeutic lymph node dissections for malignant melanomaEuropean Journal of Surgical Oncology, 2007